medRxiv preprint doi: https://doi.org/10.1101/2024.01.31.24302090; this version posted January 31, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

Performance of Immunological Assays for Universal and Differential Diagnosis of 1

HTLV-1/2 Infection in Candidates for Blood Donations from the Brazilian Amazon 2

3

Felipe Araujo Santos^{1,2}; Cláudio Lucas Santos Catão^{1,2}; Júlia Pereira Martins^{3,4}; Uzamôr 4 Henrique Soares Pessoa²; Isabelle Vasconcelos Sousa^{2,5}; Jean Silva Melo^{6,7}; Gláucia 5 Lima Souza^{1,2}; Nilberto Dias Araújo^{1,2,6}; Fábio Magalhães-Gama^{2,3,4}; Cláudia Maria de 6 Moura Abrahim²; Emmily Myrella Vasconcelos Mourão⁷; Vanessa Peruhype-Magalhães⁴; 7 Jordana Grazziela Alves Coelho-dos-Reis^{4,8}; Andréa Teixeira-Carvalho^{3,4}; Antonio 8 Carlos Rosário Vallinoto^{9,10}; Gemilson Soares Pontes^{1,6,7}; Márcio Sobreira Silva Araújo^{3,4}; 9

- Olindo Assis Martins-Filho^{1,3,4} & Allyson Guimarães da Costa^{1,2,5,6*} 10
- 11
- ¹Programa de Pós-Graduação em Ciências Aplicadas à Hematologia, Universidade do Estado 12
- 13 do Amazonas (UEA), Manaus, Brazil;
- ²Diretoria de Ensino e Pesquisa, Fundação Hospitalar de Hematologia e Hemoterapia do 14 Amazonas (HEMOAM), Manaus, Brazil; 15
- ³Programa de Pós-Graduação em Ciências da Saúde, Instituto René Rachou Fundação 16
- Oswaldo Cruz (FIOCRUZ) Minas, Belo Horizonte, Brazil; 17
- ⁴Grupo Integrado de Pesquisas em Biomarcadores, Instituto René Rachou FIOCRUZ Minas, 18
- Belo Horizonte, Brazil; 19
- ⁵Programa de Pós-Graduação em Enfermagem, Escola de Enfermagem de Manaus, 20
- Universidade Federal do Amazonas (UFAM), Manaus, Brazil; 21
- ⁶Programa de Pós-Graduação em Imunologia Básica e Aplicada, Instituto de Ciências Biológicas, 22
- 23 UFAM, Manaus, Brazil;
- 24 ⁷Laboratório de Virologia, Instituto Nacional de Pesquisa da Amazônia (INPA), Manaus, Brasil;
- ⁸Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas 25
- 26 Gerais (UFMG); Belo Horizonte, Brazil;
- ⁹Programa de Pós-graduação em Biologia de Agentes infecciosos e Parasitários, Universidade 27
- Federal do Pará (UFPA), Belém, Brasil; 28
- 29 ¹⁰Laboratório de Virologia, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém,
- 30 Brazil.
- 31
- *Correspondence: Allyson Guimarães da Costa, Rua Terezina, 495, Adrianópolis, Manaus, 32
- CEP: +55 E-mail: 33 Amazonas, Brazil, 69057-070. Phone: 92 98153-5233. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 34 allyson.gui.costa@gmail.com

35 ABSTRACT

study compares the ability of distinct immunological 36 The present assavs (chemiluminescence immunoassay-CLIA, western blot-WB and flow cytometry-FC-37 38 Simplex and Duplex) to detect anti-HTLV antibodies in candidates for blood donations at the Amazonas State Blood Center (Brazil) between January 2018 and December 2022. 39 Overall, 257,942 samples from candidates for blood donations were screened using 40 CLIA, which led to 0.15% seropositivity for HTLV (409 samples). A total of 151 candidates 41 for blood donations were enrolled for retesting with CLIA followed by additional testing 42 using WB and FC-Simplex and Duplex analysis. Our results demonstrated that 62% 43 (93/151), 20% (30/151) and 17% (26/151) of the samples presented positive results with 44 retesting using CLIA, WB and FC-Simplex analysis, respectively. Additional analysis of 45 the CLIA, WB and FC-Simplex results revealed an overall agreement of 56% for CLIA 46 and WB (22 co-negative; 30 co-positive samples), 48% for CLIA and FC-Simplex (21 co-47 negative; 24 co-positive samples) and 80% for WB and FC-Simplex (51 co-negative; 23 48 co-positive samples). Considering the WB as the reference standard for the diagnosis of 49 infection with HTLV-1/2, we observed that the CLIA results of ≤3.0 RLU and >10.0 RLU 50 in the retest can be used define a negative or positive result, respectively, and could be 51 used as new specific cut-off values. The overall agreement between WB and FC-Duplex 52 for accomplishing the differential diagnosis was evaluated and demonstrated 100% 53 correspondence for the diagnosis of HTLV-1 (15/15) and HTLV-2 (7/7). Our findings 54 demonstrate that gaps in the diagnosis of infection with HTLV-1/2 could be overcome by 55 the simultaneous use of distinct immunological assays during retesting of candidates for 56 57 blood donations.

58

59 **Keywords:** HTLV-1/2, universal diagnosis, differential diagnosis, sensitivity, specificity.

60

61 **1. INTRODUCTION**

Discovered in 1980, human T-lymphotropic virus (HTLV) is an oncogenic retrovirus that has 4 types (HTLV-1, HTLV-2, HTLV-3 and HTLV-4). HTLV-1 and HTLV-2 are viruses that are considered to be of medical importance and are related to adult T-cell leukemia/lymphoma (ATLL), neurodegenerative diseases such as HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) and hairy cell infections [1–3]. It is estimated that 3 to 5% of HTLV-1 infections may evolve into these pathologies, while

HTLV-2 infection still needs to be better characterized regarding its relationship with these
 clinical diseases [4–10].

Transmission of the virus in humans can occur through sexual contact, blood 70 71 transfusions, transplants with contaminated organs, breastfeeding of newborns and accidents with or sharing of contaminated sharp instruments [7,11-13]. HTLV-1/2 72 infections are estimated to affect approximately 10 to 20 million people worldwide and 73 depending on the region, prevalence can range between 5% and 27% [1,14]. Areas of 74 Japan, the Caribbean Islands, Africa, South America, some regions of Romania and the 75 Middle East are endemic for HTLV-1, while HTLV-2 is found in pygmies in Central 76 America, African countries, and indigenous populations of the Americas [1,2,15]. 77

In Brazil, the first cases of HTLV were detected in 1986, in a community of 78 Japanese descendants in Mato Grosso do Sul [16]. Subsequently, the detection of the 79 virus in different Brazilian regions and states was described, with a greater number of 80 81 cases in the states of Bahia, Maranhão and Pará, although the infection is considered 82 endemic and has a heterogeneous distribution [17,18]. In the northern region of Brazil, reports have shown a high prevalence of HTLV-1/2 infection in blood donors from the 83 states of Amapá (0.71%) and Pará (0.91%), although in Amazonas the number of cases 84 is considered low (0.13%) [19-21]. 85

86 Due to their higher sensitivity, the screening of patients or blood donors for HTLV-1/2 is initially carried out with the enzyme immunosorbent assay (ELISA), 87 chemiluminescent immunoassay (CLIA) and the particle agglutination assay (PA). 88 Subsequently, confirmatory assays are performed using western blot (WB), line 89 immunoassay (INNO-LIA) and guantitative real-time polymerase chain reaction (gPCR). 90 These assays have a high specificity for detecting specific antibodies for different HTLV 91 antigens, as well as molecular detection of the genetic material of the provirus [22,23]. In 92 addition to these tests, a new method for screening and differential diagnosis of HTLV-93 1/2 infection based on the flow cytometry technique presented promising results for 94 screening with the FC-Simplex IgG1 (HTLV) and differential diagnosis for HTLV-1/2 95 96 infection with the FC-Duplex IgG1 (HTLV-1/2) assay [24–26].

WB is considered to be the reference standard for the detection and diagnosis of
HTLV-1/2 infection, although it has limitations regarding seroconversion in newly infected
individuals, in addition to high costs due to the limited availability of tests [27–29].
Moreover, the difficulty of automating these assays is noted, with the use of CLIA being

proposed for blood centers since it has excellent sensitivity and the ability to track infection, despite false-positive results [28,30–32]. Thus, a study was carried out in order to compare the performance of distinct immunological assays (CLIA, WB, FC-Simplex and Duplex) to detect anti-HTLV antibodies in candidates for blood donations at the Amazonas State Blood Center (Brazil).

106

107 2. MATERIALS AND METHODS

108

109 2.1 Study design

A longitudinal study was carried out with blood donor candidates from the state of Amazonas, Brazil, who were evaluated at the Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (HEMOAM) and who had a positive result for HTLV-1/2 infection via the CLIA in the period from January 2018 to December 2022. The state of Amazonas has a low prevalence of HTLV-1/2 infection, which was previously estimated to be 0.13% [20].

116 **2.2 Ethical statement**

Ethical approval for the study was obtained from the Research Ethics Committee 117 at the HEMOAM Foundation (approval number #5.348.608, CAEE: 118 57153922.5.0000.0009). All procedures are in accordance with Resolution 466/12 of the 119 Brazilian Ministry of Health and the Declaration of Helsinki. All the participants read and 120 signed the informed consent form before enrollment. 121

122

2.3 Characteristics of the study population

123 Individuals aged 18 years or older who were seropositive for anti-HTLV-1/2 in the 124 CLIA screening test were interviewed. Those who accepted and signed the informed 125 consent form (ICF) were subjected to a CLIA retest, in addition to the WB, FC-Simplex 126 and FC-Duplex assays. The results of immunological assays were not used for medical 127 decisions regarding diagnosis and treatment. Furthermore, participants who tested 128 positive for HTLV-1 or HTLV-2 infection via the WB assay were considered to have a 129 defined diagnosis.

130

131 **2.4Acquisition of clinical and laboratory data**

Sociodemographic and clinical information was collected through a questionnaire
 and from the records of the Serology Laboratory using the HEMOSYS system.
 HEMOSYS data were updated at the time of applying the ICF.

135 **2.5 Collection and processing of biological samples**

Venous blood for immunological assays was collected using a vacuum system in tubes with EDTA and separating gel (BD Vacutainer EDTA® K2 and BD gel SST® Advance II). Subsequently, the biological samples were centrifuged, and aliquots of ±700 uL were prepared and frozen at -80 °C until the CLIA, WB, FC-Simplex and FC-Duplex assays were carried out.

141 **2.6 Chemiluminescence assay (CLIA)**

The chemiluminescence assay (CLIA) was carried out in the serology sector of the 142 143 HEMOAM Foundation as a screening and retesting step to detect donors that were positive for HTLV-1/2 infection. The procedure consists of a two-step immunoassay for 144 the qualitative detection of antibodies to HTLV-1 and HTLV-2 in serum, using the Alinity 145 s rHTLV-I/II kit (Abbott®). The immunoassay is performed with a closed system and 146 chemiluminescent microparticle technology (Alinity i-SCM 02 Ai01767, Abbott®). The 147 tests were carried out following the guidelines of the kit and equipment's manufacturers, 148 with results expressed in relative light units (RLU). 149

150

2.7 Western blot assay

The western blot (WB) assay was performed with the HTLV blot 2.4 kit (MP diagnostics[®]), following the guidelines of the manufacturer of the kit. The WB is qualitative enzyme immunoassay uses for detection of the antibodies to HTLV-1/2 in human serum and is used as a confirmatory step methodology that is capable of detecting and distinguishing virus types 1 and 2, generating positive, negative or indeterminate results.

156 **2.8 Flow cytometry assay**

The FC-Simplex IgG1 (HTLV) assay was developed as a qualitative support methodology for the detection of infections with HTLV, and uses commercial cells infected with the virus [24,26]. This technology uses a system for detecting IgG1 antibodies on a competitive immunofluorescence platform using flow cytometry, with MT-2 cells as antigenic support. The assay aims to select positive samples, but without distinguishing between viral types, and functions as a screening step for FC-Duplex IgG1 HTLV.

Subsequently, the FC-Duplex IgG1 (HTLV-1/2) assay was performed as a supporting 163 assay for the differential diagnosis of HTLV-1/2 infection, using commercial cells infected 164 with the viruses [25]. The assay uses a system for detecting IgG1 antibodies in a 165 competitive immunofluorescence platform using flow cytometry, using MT-2 and MoT cell 166 lines stained with the fluorochrome Alexa Fluor 647 (AF647) as antigenic support. In both 167 tests, the results are expressed as a percentage of positive fluorescent cells (PPFC), 168 which were obtained with the detection system after acquiring the samples in the 169 170 FACSCalibur cytometer and analyzing the MFI with the FlowJo software (v10.1).

171 **2.9 Statistical analysis**

Prisma GraphPad Software version v.8.1 (GraphPad Prism, San Diego, CA, USA) was used to create graphs and perform the statistical analyses. The Shapiro-Wilk test was used to verify the distribution and normality of the variables, which showed a nonparametric distribution. Comparison of RLU and PFFC data was performed using the Mann-Whitney test. The level of statistical significance in all the analyses was defined as p<0.05.

178

179 **3. RESULTS**

During the study period (Jan, 2018 to Dec, 2022), 409 samples from the 257,942 candidates for blood donations (0.15%) presented a positive result for anti-HTLV-1/2 IgG during screening using the CLIA, which was carried out at HEMOAM. The median reactivity of the positive samples was 1.79 RLU. **Table 1** summarizes the demographical and laboratorial records of the candidates for blood donations with positive results for HTLV-1/2 during serological screening using the CLIA.

After the initial screening using the CLIA, donor candidates with positive results 186 were invited to provide a new blood sample for retesting using the CLIA to confirm 187 seropositivity for HTLV-1/2 antibodies (Figure 1). A total of 151 donor candidates agreed 188 to participate in the retesting using the CLIA. Data analysis revealed that 93 out of the 189 151 samples (62%) exhibited positive results in the retest with the CLIA, with a median 190 191 reactivity of 2.50 RLU (Figure 1a). Comparative analysis between positive CLIA results obtained during screening and the retest presented a high correlation "r" score (0.89, 192 p<0.0001) (Figure 1b). 193

The 93 samples were additionally tested using two other immunological tests (WB 194 and FC-Simplex). The results demonstrated that 30 samples (20%) presented positive 195 results in the WB and 26 (17%) in the FC-Simplex (Supplementary Table 1). Additional 196 analysis of the scattering distribution of the CLIA results of the retesting allowed the 197 identification of three clusters, which were further classified as: low RLU (1.0-1.3), 198 intermediate RLU (>1.3-3.0) and high RLU (>3.0-400), comprising 22%, 35% and 43% of 199 tested samples, respectively. Data from the WB were also classified into three categories, 200 201 considering the band profiles, as: negative (no reactivity or reactivity to proteins other than p19 or p24), indeterminate (reactivity to HTLV specific bands that do not meet the 202 criteria for HTLV-1/2 seropositivity) and positive results (reactivity to p19, GD21 and 203 204 rgp46-I for HTLV-1 or reactivity to p24, GD21 and rgp46-II for HTLV-2), comprising 57%, 11% and 32% of the tested samples, respectively. The results of FC-Simplex analysis 205 206 were subsequently classified into two categories according to the magnitude of the PPFC results as: negative (PPFC≤20%) and positive (>20%) comprising 74% and 26% of the 207 208 tested samples, respectively (Figure 2a).

For further analysis of the results obtained during the retesting, the data from the 209 CLIA, WB and FC-Simplex were analyzed considering the distinct categories of results 210 obtained in each assay (low, intermediate and high - CLIA, positive, negative and 211 indeterminate - WB, negative and positive - FC), as previously proposed in the Figure 212 2a. Comparative analysis of the CLIA and WB revealed an overall agreement of 56% (22 213 co-negative and 30 co-positive samples), while the CLIA and FC-Simplex yielded 48% of 214 agreement (21 co-negative and 24 co-positive samples). Comparison between the WB 215 216 and FC-Simplex demonstrated higher agreement (80%) with 51 co-negative and 23 copositive samples (Figure 2b). 217

Using the WB as a reference method for confirmatory diagnosis of HTLV-1/2 infection, our findings demonstrated that any CLIA result of \leq 3.0 RLU should be considered a negative result while a CLIA result of >10.0 RLU should define a positive result.

In order to accomplish the differential diagnosis of HTLV-1 and HTLV-2 infection, the WB and the FC-Duplex assay were carried out in parallel batches. The WB results for HTLV-1 from HTLV-2 for differential diagnosis were considered according to the manufacturer instructions and the FC-Duplex results were classified using the criteria previously proposed by Pimenta de Paiva et al. [25]. According to their criteria, the

differential diagnosis of HTLV infection using FC-Duplex can be achieved as the △PPFC 227 = (MT-2 1:32 - Mot 1:32). Using this criterion, out of 22 of the tested samples, fifteen were 228 classified as HTLV-1 and seven as HTLV-2. Comparative analysis between the WB and 229 FC-Duplex results (criterion 1) demonstrated 100% agreement for HTLV-1 (15/15) and 230 HTLV-2 (7/7) (Figure 3). Pimenta de Paiva et al. [25] proposed two additional criteria for 231 differential diagnosis of HTLV infection using FC-Duplex. The use of these criteria did not 232 show outstanding agreement when compared with the WB reference diagnosis [criterion 233 2 (HTLV-1 (15/15), HTLV-2 (4/7) with 3/7 misclassifications); criterion 3 (HTLV-1 (15/15), 234 HTLV-2 (5/7) with 2/7 misclassifications)] (Supplementary Figures 1 and 2). 235

236

237 4. DISCUSSION

During the 5 years of screening blood donors that were reactive for HTLV-1/2 at 238 239 the HEMOAM Foundation, we detected 409 individuals who were considered unfit to donate due to reactive serology for the virus when using the CLIA. At the time of the 240 241 donation attempt, these individuals are flagged in the HEMOSYS system as having pending issues. They are subsequently contacted by the blood center and asked to return 242 243 for a retest to confirm the diagnosis. This procedure occurs in accordance with guidance of the Brazilian Ministry of Health and Law 17,344, which makes the diagnosis and 244 monitoring of individuals infected with HTLV mandatory, so that they can be treated for 245 their serological condition [22]. 246

During the study period (2018 to 2022), we identified a prevalence of 0.15% of 247 anti-HTLV antibodies (n= 257,942 eligible donors during the study period). We observed 248 a slight increase in this prevalence when we compared it with data from previous surveys 249 carried out in the same region of Brazil, which identified a prevalence of 0.13% (n=87,402) 250 in the period from 2001 to 2003, and 0.14% (n=6,865) in the period from 2008 to 2009 251 when using ELISA. This indicates that the prevalence in the state was generally 252 maintained [20,33]. It is important to consider that the present study presented a longer 253 survey period and covered a greater number of donors, though a similar prevalence was 254 observed. These data demonstrate that Amazonas continues to be one of the states with 255 the lowest prevalence when compared to others in the northern region of Brazil, such as 256 Amapá (0.71%) and Pará (0.91%) [34,35]. 257

258 Despite the low prevalence of HTLV-reactive blood donors in the city of Manaus, 259 new studies must be carried out, especially considering other populations that are not

blood donors, such as riverine and indigenous people. Conducting research with other populations would provide complementary data and give a better overview of the prevalence of the HTLV virus in Amazonas. If new surveys are carried out on blood donors, it would be interesting to use the same assay methodologies as in the present study, with the aim of providing a safer comparison, taking into account that ELISA and CLIA may differ in terms of the screening and diagnosis process [30,35,36].

In our study, of the 151 individuals resubmitted to the CLIA, 93 (62%) were positive 266 and were selected to undergo confirmatory retests. Using the WB, the main methodology 267 used to confirm the type of HTLV, we identified 30 (20%) positive, 10 (7%) indeterminate 268 and 111 (73%) negative samples. In addition, via the FC-Simplex, 26 (29%) positive and 269 67 (71%) negative samples for HTLV were identified. Indeterminate cases in the WB 270 assay may be associated with the individual's seroconversion period, as well as cross 271 reactions, which make accurate diagnosis of HTLV difficult. Cross-reactivity may be linked 272 to individuals who had a recent *P. falciparum* infection, as studies in endemic areas have 273 shown that infection by the parasite can interfere with the result and is capable of 274 producing false positives in the WB [37]. Noteworthy, the Amazon is considered an 275 endemic area for malaria in the country, with 99% of autochthonous cases, and this could 276 contribute to the number of indeterminate cases observed [35,38]. 277

Regarding the comparison of the assays evaluated, when we categorized them 278 279 into low, intermediate and high RLU (Figure 2a) according to the CLIA sensitivity cut-off point, it was identified that the low and intermediate zones were negative in the WB and 280 281 the FC-Simplex. The CLIA's very low cut-off point is a good factor for using this methodology as a screening test, as has been observed in other studies carried out to 282 verify the application of this assay during screening [30-32,36]. However, false-positive 283 results in immunological assays need to be evaluated and minimized, as this impacts the 284 quality of life of candidates for blood donations with a positive result during screening 285 tests. In our study, we propose that the RLU values currently used in the CLIA need to 286 be revised, and any CLIA results of ≤3.0 RLU should be considered negative results 287 while CLIA results of >10.0 RLU would define a positive result. Other studies reinforce 288 these findings and state that the assays need to be revised, and sequential tests can be 289 used, with different methodologies or adjustments in the cutoff values in the CLIA used 290 to screen blood donors in Brazil, thus avoiding the use of confirmatory assays [39-41]. 291

Despite the CLIA's weaknesses in relation to the seroconversion period of 292 individuals, in addition to cross-reactivity, the test appears to be efficient in preventing the 293 passage and distribution of blood bags contaminated with the HTLV virus. However, it 294 does not have the same efficiency when used as a diagnostic method for the virus, due 295 to its low agreement (56%) when compared to the WB. On the other hand, the FC-296 Simplex assay (still in the validation phase) showed better performance (agreement = 297 80%), and can be used to confirm the screening process, before confirming the differential 298 299 diagnosis with the WB or qPCR [26]. Additionally, we observed that the FC-Duplex, the assay responsible for the viral distinction between HTLV-1 and HTLV-2 as a phase after 300 FC-Simplex, also presented excellent results, with 100% agreement when compared to 301 302 the WB for the samples analyzed [25,26]. Although these results are promising, we note that only criterion 1 (MT-2 1;32 minus MoT 1;32) was considered satisfactory for 303 304 agreement with the WB results, whereby 15 (100%) reactive samples were identified for HTLV-1 and 7 (100%) for HTLV-2. This highlights the ability of the FC-Duplex to 305 306 distinguish other viruses from HTLV, while also being a low cost and accessible assay for blood banks in Brazil [25]. 307

It is important to highlight that our study has some limitations. In the initial survey 308 of individuals that were reactive for HTLV, 409 blood donors that were reactive for the 309 virus were identified. However, due to the lack of updating of records in the institution's 310 database, it was not possible to obtain contact with a significant number of individuals, 311 and a large portion did not show interest in returning for a new CLIA, which ended up 312 having a significant impact on the number of participants in the study. In addition, we did 313 314 not perform the qPCR technique, which would have provided valuable data for comparison with other methodologies, in addition to being useful to elucidate the 315 316 serological status of the ten samples that were categorized as indeterminate in the WB. Finally, due to the state of Amazonas being an endemic area for malaria, it is important 317 to evaluate possible co-infection in these individuals so as to eliminate possible biases. 318

319

320 5. CONCLUSION

Our results demonstrate the low seroprevalence of HTLV among candidates for blood donation in the state of Amazonas. They also demonstrate that levels are lower than those of other states in the northern region of Brazil. We also showed that the CLIA is highly effective in the screening stage of candidates for blood donations, although it

presents many false-positive results and the need for confirmatory tests. In addition, FCsimplex and FC-Duplex were able to identify reactive samples, and could make the distinction between HTLV-1/2. It is therefore a promising methodology for confirming HTLV infection when compared with WB, which is the reference assay. Furthermore, our findings indicate that gaps in the diagnosis of HTLV-1/2 infection could be overcome by the simultaneous use of distinct immunological assays during retesting of candidates for blood donations.

332

333 DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

336

337 ETHICS STATEMENT

The present study was submitted to and approved by the Ethical Committee at Fundação HEMOAM, under the protocol registration number #739.563/2014. The participants read and signed the informed consent form prior to inclusion in the study. The study fulfills the principles of the Declaration of Helsinki and resolution 466/2012 of the Brazilian National Health Council for research involving human participants.

343

344 CONFLICT OF INTEREST

345 The authors declare that the research was conducted in the absence of any commercial

or financial relationships that could be construed as a potential conflict of interest.

347

348 AUTHOR CONTRIBUTIONS

FAS, JGAC-R, AT-C, MSSA, GSP, OAM-F and AGC conceptualized and designed the
study. FAS, CLSC, JPM, UHSP, IVS, JSM, GLS, NDA, EMVM, CMMA and AGC recruited
all the individuals for the study and performed the experiments. FAS, JPM, MSSA, OAM-F
and AGC analyzed the data. FAS, MSSA, OAM-F and AGC wrote the manuscript. VP-M,
JGAC-R, AT-C, ACRV, GSP, FM-G, OAM-F and AGC revised the manuscript. All authors
read and approved the final version of the manuscript.

355

356 FUNDING

Financial support was provided in the form of grants from Fundação de Amparo à 357 Pesquisa do Estado do Amazonas (FAPEAM) (Pró-Estado Program #002/2008, 358 #007/2018 and #005/2019, PRODOC Program #003/2022; STARTUP PARA O SUS 359 Program #012/2022 and POSGRAD Program #002/2023), Fundação de Amparo à 360 Pesquisa do Estado de Minas Gerais (FAPEMIG) (APQ-00821-20 - PPSUS Program 361 #03/2020), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPg) and 362 Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) (PROCAD-363 364 Amazônia 2018 Program - #88881.200581/2018-01). FAS, CLSC, JPM, IVS and GLS have fellowships from FAPEAM, FAPEMIG and CAPES (MSc students). JSM was 365 research fellow from CAPES (PhD student). UHSP have fellowships from FAPEAM 366 (scientific initiation student). JGAC-R, ACRV, MSSA, OAM-F and AGC are research 367 fellows from CNPq. OAM-F participated in the fellowship program supported by the 368 Universidade do Estado do Amazonas (PROVISIT Nº 005/2023-PROPESP/UEA). The 369 funders had no role in study design, the decision to publish, or preparation of the 370 manuscript. 371

372

373 **REFERENCES**

- Gessain A, Cassar O. Epidemiological Aspects and World Distribution of HTLV-1
 Infection. Front Microbiol. 2012;3. doi:10.3389/fmicb.2012.00388
- Roucoux DF, Murphy EL. The epidemiology and disease outcomes of human T lymphotropic virus type II. AIDS Rev. 2004;6: 144–54.
- Mahieux R, Gessain A. HTLV-3/STLV-3 and HTLV-4 Viruses: Discovery,
 Epidemiology, Serology and Molecular Aspects. Viruses. 2011;3: 1074–1090.
 doi:10.3390/v3071074
- Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, Miyoshi I, Blayney D,
 Golde D, et al. A New Subtype of Human T-Cell Leukemia Virus (HTLV-II)
 Associated with a T-Cell Variant of Hairy Cell Leukemia. Science (1979). 1982;218:
 571–573. doi:10.1126/science.6981847
- 3855.Uchiyama T. HUMAN T CELL LEUKEMIA VIRUS TYPE I (HTLV-I) AND HUMAN386DISEASES.AnnuRevImmunol.1997;15:15–37.387doi:10.1146/annurev.immunol.15.1.15
- Castro-Costa CM De, Araújo AQC, Barreto MM, Takayanagui OM, Sohler MP, Silva
 ELM Da, et al. Proposal for Diagnostic Criteria of Tropical Spastic
 Paraparesis/HTLV-I-Associated Myelopathy (TSP/HAM). AIDS Res Hum
 Retroviruses. 2006;22: 931–935. doi:10.1089/aid.2006.22.931

- Martinez MP, Al-Saleem J, Green PL. Comparative virology of HTLV-1 and HTLV Retrovirology. 2019;16: 21. doi:10.1186/s12977-019-0483-0
- Takatani M, Crispim ME, Fraiji N, Stefani MMA, Kiesslich D. Clinical and laboratory features of HTLV-I asymptomatic carriers and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis from the Brazilian Amazon. Rev Inst Med Trop Sao Paulo. 2017;59. doi:10.1590/s1678-9946201759005
- Blanco S, Barile ME, Frutos MC, Vicente ACP, Gallego SV. Neurodegenerative disease in association with sexual transmission of human T-cell lymphotropic virus type 2 subtype b in Argentina. Trans R Soc Trop Med Hyg. 2022;116: 622–627. doi:10.1093/trstmh/trab173
- Vallinoto ACR, Gonçalves JSS, Abreu IN, de Oliveira Freitas V, Lima CNC, Botelho
 BS, et al. Unique evidence of atypical lymphocytes and flower cells in indigenous
 Xikrin do Bacajá people infected with HTLV-2. Journal of Clinical Virology Plus.
 2023;3: 100155. doi:10.1016/j.jcvp.2023.100155
- 40611.Gross C, Thoma-Kress AK.Molecular mechanisms of HTLV-1 cell-to-cell407transmission. Viruses. 2016. doi:10.3390/v8030074
- Igakura T, Stinchcombe JC, Goon PKC, Taylor GP, Weber JN, Griffiths GM, et al.
 Spread of HTLV-I Between Lymphocytes by Virus-Induced Polarization of the
 Cytoskeleton. Science (1979). 2003;299: 1713–1716.
 doi:10.1126/science.1080115
- 412 13. Verdonck K, González E, Van Dooren S, Vandamme A-M, Vanham G, Gotuzzo E.
 413 Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet
 414 Infect Dis. 2007;7: 266–281. doi:10.1016/S1473-3099(07)70081-6
- Willems L, Hasegawa H, Accolla R, Bangham C, Bazarbachi A, Bertazzoni U, et al.
 Reducing the global burden of HTLV-1 infection: An agenda for research and action. Antiviral Res. 2017;137: 41–48. doi:10.1016/j.antiviral.2016.10.015
- 418 15. Beilke MA. Retroviral Coinfections: HIV and HTLV: Taking Stock of More Than a
 419 Quarter Century of Research. AIDS Res Hum Retroviruses. 2012;28: 139–147.
 420 doi:10.1089/aid.2011.0342
- 421 16. Kitagawa T. Antibodies to HTLV-I in Japanese Immigrants in Brazil. JAMA: The
 422 Journal of the American Medical Association. 1986;256: 2342.
 423 doi:10.1001/jama.1986.03380170058009
- 424 17. Catalan-Soares BC, Proietti FA, Carneiro-Proietti AB de F. Os vírus linfotrópicos
 425 de células T humanos (HTLV) na última década (1990-2000): aspectos
 426 epidemiológicos. Revista Brasileira de Epidemiologia. 2001;4: 81–95.
 427 doi:10.1590/S1415-790X2001000200003
- 18. Carneiro-Proietti ABF, Ribas JGR, Catalan-Soares BC, Martins ML, Brito-Melo
 GEA, Martins-Filho OA, et al. Infecção e doença pelos vírus linfotrópicos humanos
 de células T (HTLV-I/II) no Brasil. Rev Soc Bras Med Trop. 2002;35: 499–508.
 doi:10.1590/S0037-86822002000500013

- 432 19. Galvao-Castro B, Loures L, Rodriques L, Sereno A, Ferreira Junior O, Franco L, et
 433 al. Distribution of human T-lymphotropic virus type I among blood donors: a
 434 nationwide Brazilian study. Transfusion (Paris). 1997;37: 242–243.
 435 doi:10.1046/j.1537-2995.1997.37297203532.x
- 436 20. Morais MPE de, Gato CM, Maciel LA, Lalwani P, Costa CA, Lalwani JDB.
 437 Prevalence of Human T-lymphotropic virus type 1 and 2 among blood donors in
 438 Manaus, Amazonas State, Brazil. Rev Inst Med Trop Sao Paulo. 2017;59.
 439 doi:10.1590/s1678-9946201759080
- 21. Catalan-Soares B, Carneiro-Proietti AB de F, Proietti FA. Heterogeneous 440 geographic distribution of human T-cell lymphotropic viruses I and II (HTLV-I/II): 441 serological screening prevalence rates in blood donors from large urban areas in 442 Brazil. Cad Saude Publica. 2005;21: 926-931. doi:10.1590/S0102-443 311X2005000300027 444
- Rosadas C, Brites C, Arakaki-Sánchez D, Casseb J, Ishak R. Protocolo Brasileiro para Infecções Sexualmente Transmissíveis 2020: infecção pelo vírus linfotrópico de células T humanas (HTLV). Epidemiologia e Serviços de Saúde. 2021;30. doi:10.1590/s1679-497420200006000015.esp1
- 449 23. Moreno C, Balangero M, Barbás MG, Cudolá A, Gallego S. Diagnóstico serológico de HTLV-1/2: combinación de técnicas de tamizaje para definir el estatus serológico en donantes de sangre. Rev Argent Microbiol. 2013;45: 165–168. doi:10.1016/S0325-7541(13)70019-1
- 453 24. Coelho-dos-Reis JGA, Martins-Filho OA, de Brito-Melo GEA, Gallego S, Carneiro454 Proietti AB, Souza JG, et al. Performance of IgG and IgG1 anti-HTLV-1 reactivity
 455 by an indirect immunofluorescence flow cytometric assay for the identification of
 456 persons infected with HTLV-1, asymptomatic carriers and patients with myelopathy.
 457 J Virol Methods. 2009;160: 138–148. doi:10.1016/j.jviromet.2009.05.007
- Pimenta de Paiva L, Coelho-dos-Reis JGA, Trindade BC, Peruhype-Magalhães V,
 Silva Araújo MS, Gonçalves JJ, et al. A New Flow Cytometry-Based Single Platform
 for Universal and Differential Serodiagnosis of HTLV-1/2 Infection. Front Immunol.
 2022;13. doi:10.3389/fimmu.2022.795815
- 26. Coelho-dos-Reis JG, Peruhype-Magalhães V, Pascoal-Xavier MA, de Souza
 Gomes M, do Amaral LR, Cardoso LM, et al. Flow cytometric-based protocols for
 assessing anti-MT-2 IgG1 reactivity: High-dimensional data handling to define
 predictors for clinical follow-up of Human T-cell Leukemia virus type-1 infection. J
 Immunol Methods. 2017;444: 36–46. doi:10.1016/j.jim.2017.02.006
- 467 27. Martins ML, Santos AC da S, Namen-Lopes MS, Barbosa-Stancioli EF, Utsch DG,
 468 Carneiro-Proietti AB de F. Long-term serological follow-up of blood donors with an
 469 HTLV-Indeterminate Western Blot: Antibody Profile of Seroconverters and
 470 Individuals With False Reactions. J Med Virol. 2010;82: 1746–1753.
 471 doi:10.1002/jmv.21881
- Amen-Lopes MSS, Martins ML, Drummond PC, Lobato RR, Carneiro-Proietti
 ABF. Lookback study of HTLV-1 and 2 seropositive donors and their recipients in

- 474 Belo Horizonte, Brazil. Transfusion Medicine. 2009;19: 180–188. 475 doi:10.1111/j.1365-3148.2009.00932.x
- 29. Campos KR, Santos FLN, da Silva Brito V, Gonçalves NLS, Araujo THA, GalvãoCastro B, et al. Line Immunoassay for Confirmation and Discrimination of Human
 T-Cell Lymphotropic Virus Infections in Inconclusive Western Blot Serum Samples
 from Brazil. J Clin Microbiol. 2019;58. doi:10.1128/JCM.01384-19
- Kiely P, Walker K, Parker S, Cheng A. Analysis of sample-to-cutoff ratios on chemiluminescent immunoassays used for blood donor screening highlights the need for serologic confirmatory testing. Transfusion (Paris). 2010;50: 1344–1351. doi:10.1111/j.1537-2995.2009.02572.x
- Tosswill JHC, Taylor GP. Interpretation of low reactivity in the Abbott Architect
 rHTLV I/II assay. Transfusion Medicine. 2018;28: 326–330. doi:10.1111/tme.12482
- 486 32. Yun SG, Kim S, Sohn JY, Cho Y. Evaluation of Elecsys HTLV-I/II assay in
 487 comparison with ARCHITECT rHTLV-I/II assay with Korean samples. J Clin Lab
 488 Anal. 2019;33. doi:10.1002/jcla.22909
- da Motta Passos LN, de Moraes MPE, Tamegão-Lopes B, de Lemos JAR, de Lima
 Machado PR, Mira MT, et al. Absence of HTLV-1/2 infection and dermatological
 diseases in Manaus, State of Amazonas, Brazil. Rev Soc Bras Med Trop. 2014;47:
 507–509. doi:10.1590/0037-8682-0196-2013
- Catalan-Soares B, Carneiro-Proietti AB de F, Proietti FA. Heterogeneous 493 34. geographic distribution of human T-cell lymphotropic viruses I and II (HTLV-I/II): 494 serological screening prevalence rates in blood donors from large urban areas in 495 Brazil. Cad Saude Publica. 2005;21: 926-931. doi:10.1590/S0102-496 311X2005000300027 497
- 498 35. Ishak R, de Oliveira Guimarães Ishak M, Vallinoto ACR. The challenge of
 499 describing the epidemiology of HTLV in the Amazon region of Brazil. Retrovirology.
 500 2020;17: 4. doi:10.1186/s12977-020-0512-z
- 50136.Guiraud V, Crémoux F, Leroy I, Cohier J, Hernandez P, Mansaly S, et al.502Comparison of two new HTLV-I/II screening methods, Abbott Alinity i rHTLV-I/II and503Diasorin LIAISON® XL murex recHTLV-I/II, to Abbott architect rHTLVI/II assay.504Journal of Clinical Virology. 2023;164: 105446. doi:10.1016/j.jcv.2023.105446
- 50537.Hayes CG, Burans JP, Oberst RB. Antibodies to Human T Lymphotropic Virus Type506I in a Population from the Philippines: Evidence for Cross-Reactivity with507Plasmodium falciparum. Journal of Infectious Diseases. 1991;163: 257–262.508doi:10.1093/infdis/163.2.257
- 50938.Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Boletim510Epidemiológico. 2015;46: 1–5. doi:10.1590/S1415-790X2004000400010
- Seed CR, Margaritis AR, Bolton W V., Kiely P, Parker S, Piscitelli L. Improved efficiency of national HIV, HCV, and HTLV antibody testing algorithms based on sequential screening immunoassays. Transfusion (Paris). 2003;43: 226–234. doi:10.1046/j.1537-2995.2003.00304.x

- Kiely P, Walker K, Parker S, Cheng A. Analysis of sample-to-cutoff ratios on 515 40. chemiluminescent immunoassays used for blood donor screening highlights the 516 need for serologic confirmatory testing. Transfusion (Paris). 2010;50: 1344–1351. 517 doi:10.1111/j.1537-2995.2009.02572.x 518
- Vo MT, Bruhn R, Kaidarova Z, Custer BS, Murphy EL, Bloch EM. A retrospective 519 41. analysis of false-positive infectious screening results in blood donors. Transfusion 520 (Paris). 2016;56: 457-465. doi:10.1111/trf.13381 521
- 522

FIGURE CAPTIONS 523

Figure 1. Seroprevalence for anti-HTLV antibodies in candidates for blood 524 donations at the Amazonas State Blood Center. a) Anti-HTLV reactivity profile of 409 525 candidates for blood donations using CLIA during screening (2018 - 2022). CLIA results 526 of 151 candidates for blood donations at retesting (2023). b) Correlation analysis between 527 528 CLIA RLU values during screening and retesting. CLIA: chemiluminescence assay; RLU: 529 relative light units.


Figure 2. Performance of different immunological assays to detect anti-HTLV 530 antibodies, a) CLIA results were classified as low, intermediate or high based on the 531 RLU values; the western blot results were categorized as negative, indeterminate or 532 positive, according to band profile, and FC-Simplex results were defined as negative or 533 positive, according to the PPFC values. b) Comparison of CLIA vs WB, CLIA vs FC-534 535 Simplex and WB vs FC-Simplex results. CLIA: chemiluminescence assay; RLU: relative 536 light units; WB: western blot assay; PPFC: percentage of positive fluorescent cells.

Figure 3. Differential diagnosis of HTLV-1/2 infection after retesting using the FC-537 538 Duplex IgG1. a) Anti- MT-2 (1:32) and anti- MoT (1:32) reactivity used to define the HTLV-1 and HTLV-2 diagnosis according to criterion 1, previously proposed by Pimenta 539 de Paiva et al. [25]. b) Agreement between FC-Duplex HTLV-1/2 IgG1 and western blot 540 541 results. PPFC: percentage of positive fluorescent cells; WB: western blot assay.

Supplementary Figure 1. Differential diagnosis of HTLV-1/2 infection after retesting 542 543 using the FC-Duplex IgG1. a) Anti-MT-2 (1:32) and anti-MoT (1:1,024) reactivity used to define the HTLV-1 and HTLV-2 diagnosis according to criterion 1, previously proposed 544 by Pimenta de Paiva et al. [25]. b) Agreement between FC-Duplex HTLV-1/2 IgG1 and 545 western blot results. PPFC: percentage of positive fluorescent cells; WB: western blot 546 547 assay

Supplementary Figure 2. Differential diagnosis of HTLV-1/2 infection after retesting 548 using the FC-Duplex IgG1. a) Anti- MT-2 (1:32) and anti-MoT (1:2,048) reactivity used 549 to define the HTLV-1 and HTLV-2 diagnosis according to criterion 1, previously proposed 550 by Pimenta de Paiva et al. [25]. b) Agreement between FC-Duplex HTLV-1/2 IgG1 and 551 552 western blot results. PPFC: percentage of positive fluorescent cells; WB: western blot 553 assay.









Figure 1

Figure 1



a)





Figure 2

Figure 2

a)

Criterion 1 of FC-Duplex HTLV1/2 - IgG1 △PPFC = (MT-2 1:32 - Mot 1:32)






Figure 3

Figure 3